Abbott Laboratories (ABT) Tax Provisions (2009 - 2026)

Abbott Laboratories has disclosed Tax Provisions across 18 years of filings, most recently posting $372.0 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at $372.0 million, down 17.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 130.27% YoY), and the FY2025 annual result was $1.9 billion, up 130.4% from the prior year.
• Tax Provisions came in at $372.0 million for Q1 2026 at Abbott Laboratories, down from $582.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $582.0 million in Q4 2025 to a low of -$7.2 billion in Q4 2024.
• The 5-year median for Tax Provisions is $305.0 million (2024), against an average of -$103.6 million.
• Across the five-year window, Tax Provisions slumped 3681.59% in 2024 and jumped 114.69% in 2025, its largest moves.
• Abbott Laboratories' Tax Provisions stood at $287.0 million in 2022, then declined by 29.97% to $201.0 million in 2023, then plunged by 3681.59% to -$7.2 billion in 2024, then surged by 108.08% to $582.0 million in 2025, then tumbled by 36.08% to $372.0 million in 2026.
• The last three Tax Provisions figures came in at $372.0 million (Q1 2026), $582.0 million (Q4 2025), and $536.0 million (Q3 2025), per Business Quant data.